Pre-Clinical Models to Study Human Prostate Cancer.
adenocarcinoma
allografts
androgen
clustered regularly interspaced short palindromic repeats
mice
prostate
prostatic intraepithelial neoplasia
prostatic neoplasms
transgenes
tumor suppressor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Aug 2023
22 Aug 2023
Historique:
received:
18
07
2023
revised:
16
08
2023
accepted:
21
08
2023
medline:
9
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Prostate cancer is a common cancer among men and typically progresses slowly for several decades before becoming aggressive and spreading to other organs, leaving few treatment options. While large animals have been studied, the dog's prostate is anatomically similar to humans and has been used to study spontaneous prostate cancer. However, most research currently focuses on the mouse as a model organism due to the ability to genetically modify their prostatic tissues for molecular analysis. One milestone in this research was the identification of the prostate-specific promoter Probasin, which allowed for the prostate-specific expression of transgenes. This has led to the generation of mice with aggressive prostatic tumors through overexpression of the SV40 oncogene. The Probasin promoter is also used to drive Cre expression and has allowed researchers to generate prostate-specific loss-of-function studies. Another landmark moment in the process of modeling prostate cancer in mice was the orthoptic delivery of viral particles. This technology allows the selective overexpression of oncogenes from lentivirus or the use of CRISPR to generate complex loss-of-function studies. These genetically modified models are complemented by classical xenografts of human prostate tumor cells in immune-deficient mice. Overall, pre-clinical models have provided a portfolio of model systems to study and address complex mechanisms in prostate cancer for improved treatment options. This review will focus on the advances in each technique.
Identifiants
pubmed: 37686488
pii: cancers15174212
doi: 10.3390/cancers15174212
pmc: PMC10486646
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Danish Cancer Society
ID : R204-A12490
Organisme : Danish Cancer Society
ID : R231-A13828
Organisme : Danish Cancer Society
ID : R231-A14066
Références
Nat Commun. 2015 Jul 22;6:7736
pubmed: 26198641
Natl Cancer Inst Monogr. 1963 Oct;12:1-27
pubmed: 14072991
J Vis Exp. 2018 Apr 27;(134):
pubmed: 29757291
Am J Pathol. 2008 Jan;172(1):236-46
pubmed: 18156212
Cancer Cell. 2015 Jun 8;27(6):797-808
pubmed: 26058078
Neoplasia. 2008 Feb;10(2):177-88
pubmed: 18283340
Prog Clin Biol Res. 1980;37:149-60
pubmed: 6155669
Radiother Oncol. 2011 Jun;99(3):418-23
pubmed: 21723634
Nature. 1992 Mar 19;356(6366):215-21
pubmed: 1552940
Endocrinology. 2000 Dec;141(12):4698-710
pubmed: 11108285
J Clin Invest. 2018 Jan 2;128(1):381-386
pubmed: 29202479
Nature. 2009 Sep 24;461(7263):495-500
pubmed: 19741607
PLoS Biol. 2003 Dec;1(3):E59
pubmed: 14691534
Transl Androl Urol. 2019 Oct;8(5):519-528
pubmed: 31807428
Cancer Res. 2016 Nov 1;76(21):6137-6139
pubmed: 27803100
Mol Endocrinol. 1994 Feb;8(2):230-9
pubmed: 8170479
Science. 2017 Jan 6;355(6320):78-83
pubmed: 28059767
Clin Cancer Res. 2010 Oct 1;16(19):4843-52
pubmed: 20858837
Clin Microbiol Rev. 2008 Oct;21(4):583-93
pubmed: 18854481
Int J Cancer. 1998 Sep 11;77(6):887-94
pubmed: 9714059
Genes (Basel). 2017 May 25;8(6):
pubmed: 28587062
PLoS Genet. 2010 Jun 24;6(6):e1000995
pubmed: 20585617
Nat Genet. 1997 May;16(1):64-7
pubmed: 9140396
Nat Rev Urol. 2021 Oct;18(10):581-596
pubmed: 34290447
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2105-10
pubmed: 18245377
Nature. 2015 Apr 16;520(7547):353-357
pubmed: 25830880
J Nucl Med. 2018 Feb;59(2):177-182
pubmed: 28986509
Prostate. 2015 May;75(6):628-36
pubmed: 25560784
Methods Mol Med. 2003;81:89-112
pubmed: 12725117
Nat Genet. 2013 Jul;45(7):739-746
pubmed: 23727861
Cell Death Differ. 2015 Apr;22(4):574-82
pubmed: 25526087
Prostate. 1981;2(1):35-49
pubmed: 7279811
Cancers (Basel). 2022 Sep 08;14(18):
pubmed: 36139541
Nature. 2013 Jan 10;493(7431):236-40
pubmed: 23201680
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12046-51
pubmed: 22753496
Cancers (Basel). 2020 Mar 25;12(4):
pubmed: 32218271
Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):
pubmed: 29661807
Nature. 2005 Aug 4;436(7051):725-30
pubmed: 16079851
Prostate. 2010 May 1;70(6):591-600
pubmed: 19938013
Methods Mol Biol. 2019;1914:295-308
pubmed: 30729472
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43
pubmed: 7724580
Br J Cancer. 1982 Dec;46(6):904-11
pubmed: 7150484
Genes Dev. 1999 Apr 15;13(8):966-77
pubmed: 10215624
Prostate. 2005 Sep 15;65(1):1-9
pubmed: 15791629
Nature. 2011 Feb 10;470(7333):269-73
pubmed: 21289624
Cancers (Basel). 2022 Oct 13;14(20):
pubmed: 36291798
Cancer Res. 2005 Jul 1;65(13):5730-9
pubmed: 15994948
Am J Pathol. 2011 Jul;179(1):502-12
pubmed: 21703427
Oncogene. 2021 Apr;40(13):2437-2447
pubmed: 33674748
Prostate. 2007 Aug 1;67(11):1174-81
pubmed: 17516571
Sci Rep. 2019 Jul 31;9(1):11117
pubmed: 31366895
Cancer Sci. 2021 Jul;112(7):2592-2606
pubmed: 33938090
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Cancer Discov. 2014 Mar;4(3):318-33
pubmed: 24444712
Mol Cell Biol. 2002 Mar;22(5):1495-503
pubmed: 11839815
Cancer Cell. 2003 Sep;4(3):223-38
pubmed: 14522256
Prostate. 2013 Jun;73(9):1007-15
pubmed: 23389852
Cancer Cell. 2003 Sep;4(3):209-21
pubmed: 14522255
Cell. 2014 Oct 9;159(2):440-55
pubmed: 25263330
Cancer Discov. 2015 Jun;5(6):636-51
pubmed: 25829425
Oncotarget. 2019 Dec 03;10(64):6845-6854
pubmed: 31839878
Cell. 2012 Mar 2;148(5):896-907
pubmed: 22341455
Prostate. 2015 Jun 15;75(9):897-906
pubmed: 25728532
Cancer Res. 2010 Feb 1;70(3):979-87
pubmed: 20103652
Acta Oncol. 2008;47(7):1201-10
pubmed: 18661432
Nat Cancer. 2020 Nov;1(11):1082-1096
pubmed: 34085047
Cancer Res. 2003 Jul 15;63(14):3886-90
pubmed: 12873978
Cancer Res. 2016 Jan 15;76(2):283-92
pubmed: 26554830
Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1151-6
pubmed: 15657128
PLoS One. 2014 Jun 20;9(6):e100770
pubmed: 24950301
Mech Dev. 2001 Mar;101(1-2):61-9
pubmed: 11231059
Acta Oncol. 2019 Oct;58(10):1489-1494
pubmed: 31510843
Mol Cancer. 2022 Mar 30;21(1):89
pubmed: 35354467
Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562
pubmed: 29858604
Cancer Cell. 2017 Mar 13;31(3):436-451
pubmed: 28292441
Cancers (Basel). 2023 Apr 28;15(9):
pubmed: 37174009
Curr Opin Urol. 2023 Sep 1;33(5):390-395
pubmed: 37395505
J Transl Med. 2022 May 10;20(1):206
pubmed: 35538576
Cancers (Basel). 2021 Feb 26;13(5):
pubmed: 33652656
Dev Biol. 2008 Apr 15;316(2):302-11
pubmed: 18325490
Genes Dev. 2015 Jul 15;29(14):1576-85
pubmed: 26178787